Analyst Charles Zhu of LifeSci Capital maintained a Buy rating on Revolution Medicines, retaining the price target of $263.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Charles Zhu has given his Buy rating due to a combination of factors related to Revolution Medicines’ advancing pipeline and financial strength. He views the upsizing of the pivotal RASolve 301 trial in later-line RAS-mutant NSCLC as a strong signal of management’s confidence in daraxonrasib’s survival benefit, especially following encouraging data in pancreatic cancer, while noting the expanded trial should not delay key readouts.
He also highlights robust demand for the company’s early access program and sees RM-055, a next-generation catalytic RAS(ON) inhibitor, as a potentially differentiated asset with a widened therapeutic window and flexible dosing that could support broad clinical use. Combined with a cash position exceeding $4 billion after recent financings and the unchanged price target of $263, Zhu believes the company is well capitalized to execute on its development plans and justify a Buy rating on RVMD shares.
According to TipRanks, Zhu is a 5-star analyst with an average return of 25.2% and a 60.50% success rate. Zhu covers the Healthcare sector, focusing on stocks such as IDEAYA Biosciences, Revolution Medicines, and Adagene.
In another report released on May 4, H.C. Wainwright also reiterated a Buy rating on the stock with a $169.00 price target.